Drugs that contain Betamethasone Dipropionate; Calcipotriene

1. Drug name - ENSTILAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(9 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 30, 2022
Pediatric Exclusivity (PED) Jan 30, 2023

Market Authorisation Date: 16 October, 2015

Treatment: Topical treatment of plaque psoriasis in patients 12 years and older; Plaque psoriasis

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.064%;0.005% AEROSOL, FOAM;TOPICAL Prescription

2. Drug name - WYNZORA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265265 MC2 Topical composition
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Dosage Form (NDF) Jul 20, 2023

Market Authorisation Date: 20 July, 2020

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.064%;0.005% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.